The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Addressing cardiotoxicity concerns with the use of gilteritinib
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the importance of managing the potential cardiotoxicity associated with the use of gilteritinib when treating patients with acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
